MDK oligonucleotide

MDK oligonucleotide is a proprietary antisense oligonucleotide drug candidate developed to target and silence the expression of Midkine (MDK), a heparin-binding growth factor that is highly expressed in many solid tumors and associated with metastasis, poor treatment response, and poor prognosis. The drug works by interfering with the processing of Midkine mRNA, leading to reduced production of active Midkine protein in diseased tissues. Preclinical studies have shown that these antisense reagents can induce a splice-switching event resulting in truncated, non-functional Midkine protein and >90% reduction in functional MDK at the mRNA level. This mechanism has demonstrated efficacy in reducing cancer cell proliferation and tumor size in preclinical models. The program aims to develop first-in-class RNA medicines for "hard-to-treat" cancers expressing high levels of Midkine[1].

Other names

MDK RNA Oligoanti-Midkine antisense oligonucleotide